genomic correlates response ctla blockade metastatic melanoma
monoclonal antibodies directed cytotoxic t lymphocyte-associated antigen ctla- ipilimumab yield considerable clinical benefit patients metastatic melanoma inhibiting immune checkpoint activity clinical predictors response therapies remain incompletely characterized investigate roles tumor-specific neoantigens alterations tumor microenvironment response ipilimumab analyzed whole exomes pretreatment melanoma tumor biopsies matching germline tissue samples patients patients also obtained analyzed transcriptome data pretreatment tumor samples overall mutational load neoantigen load expression cytolytic markers immune microenvironment significantly associated clinical benefit however recurrent neoantigen peptide sequences predicted responder patient populations thus detailed integrated molecular characterization large patient cohorts may needed identify robust determinants response resistance immune checkpoint inhibitors
